Switch theme
Sign up to access all valuation multiples
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
2018
300
LTM Revenue $46K
LTM EBITDA -$254M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lyell Immunopharma has a last 12-month revenue (LTM) of $46K and a last 12-month EBITDA of -$254M.
In the most recent fiscal year, Lyell Immunopharma achieved revenue of $0.1M and an EBITDA of -$201M.
Lyell Immunopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lyell Immunopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $46K | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $46K | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$254M | XXX | -$201M | XXX | XXX | XXX |
| EBITDA Margin | -550362% | XXX | -328923% | XXX | XXX | XXX |
| EBIT | -$274M | XXX | -$220M | XXX | XXX | XXX |
| EBIT Margin | -594743% | XXX | -361105% | XXX | XXX | XXX |
| Net Profit | -$286M | XXX | -$343M | XXX | XXX | XXX |
| Net Margin | -620240% | XXX | -562285% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lyell Immunopharma's stock price is $9.
Lyell Immunopharma has current market cap of $2.5B, and EV of $2.3B.
See Lyell Immunopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.5B | XXX | XXX | XXX | XXX | $-1.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lyell Immunopharma has market cap of $2.5B and EV of $2.3B.
Lyell Immunopharma's trades at 37607.7x EV/Revenue multiple, and -11.4x EV/EBITDA.
Equity research analysts estimate Lyell Immunopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lyell Immunopharma has a P/E ratio of -8.9x.
See valuation multiples for Lyell Immunopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 49755.5x | XXX | 37607.7x | XXX | XXX | XXX |
| EV/EBITDA | -9.0x | XXX | -11.4x | XXX | XXX | XXX |
| EV/EBIT | -8.4x | XXX | -10.4x | XXX | XXX | XXX |
| EV/Gross Profit | 49755.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.9x | XXX | -7.4x | XXX | XXX | XXX |
| EV/FCF | -15.8x | XXX | -14.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLyell Immunopharma's last 12 month revenue growth is -50%
Lyell Immunopharma's revenue per employee in the last FY averaged $0K, while opex per employee averaged $0.7M for the same period.
Lyell Immunopharma's rule of 40 is -174479% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lyell Immunopharma's rule of X is -550486% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lyell Immunopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -50% | XXX | -42% | XXX | XXX | XXX |
| EBITDA Margin | -550362% | XXX | -328923% | XXX | XXX | XXX |
| EBITDA Growth | -19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -174479% | XXX | -328973% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -550486% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 281316% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 361205% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lyell Immunopharma acquired XXX companies to date.
Last acquisition by Lyell Immunopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Lyell Immunopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lyell Immunopharma founded? | Lyell Immunopharma was founded in 2018. |
| Where is Lyell Immunopharma headquartered? | Lyell Immunopharma is headquartered in United States of America. |
| How many employees does Lyell Immunopharma have? | As of today, Lyell Immunopharma has 300 employees. |
| Who is the CEO of Lyell Immunopharma? | Lyell Immunopharma's CEO is Dr. Lynn Seely,M.D.. |
| Is Lyell Immunopharma publicy listed? | Yes, Lyell Immunopharma is a public company listed on NAS. |
| What is the stock symbol of Lyell Immunopharma? | Lyell Immunopharma trades under LYEL ticker. |
| When did Lyell Immunopharma go public? | Lyell Immunopharma went public in 2021. |
| Who are competitors of Lyell Immunopharma? | Similar companies to Lyell Immunopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lyell Immunopharma? | Lyell Immunopharma's current market cap is $2.5B |
| What is the current revenue of Lyell Immunopharma? | Lyell Immunopharma's last 12 months revenue is $46K. |
| What is the current revenue growth of Lyell Immunopharma? | Lyell Immunopharma revenue growth (NTM/LTM) is -50%. |
| What is the current EV/Revenue multiple of Lyell Immunopharma? | Current revenue multiple of Lyell Immunopharma is 49755.5x. |
| Is Lyell Immunopharma profitable? | Yes, Lyell Immunopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lyell Immunopharma? | Lyell Immunopharma's last 12 months EBITDA is -$254M. |
| What is Lyell Immunopharma's EBITDA margin? | Lyell Immunopharma's last 12 months EBITDA margin is -550362%. |
| What is the current EV/EBITDA multiple of Lyell Immunopharma? | Current EBITDA multiple of Lyell Immunopharma is -9.0x. |
| What is the current FCF of Lyell Immunopharma? | Lyell Immunopharma's last 12 months FCF is -$145M. |
| What is Lyell Immunopharma's FCF margin? | Lyell Immunopharma's last 12 months FCF margin is -314985%. |
| What is the current EV/FCF multiple of Lyell Immunopharma? | Current FCF multiple of Lyell Immunopharma is -15.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
